Literature DB >> 22023903

Teriparitide update.

Stuart L Silverman1, Keaton Nasser.   

Abstract

Teriparitide (TPD) is a novel anabolic agent that stimulates bone formation. TPD reduces risk of vertebral and nonvertebral fracture. Due to its positive effects on bone formation, many new uses of TPD are being explored. It has been studied and approved for glucocorticoid-induced osteoporosis. Many questions about the use of TPD remain including use of follow-up therapy, combination therapy, sequential therapy, and its potential role in fracture healing and treatment of back pain related to osteoporosis.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22023903     DOI: 10.1016/j.rdc.2011.08.002

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  3 in total

1.  Intermittent parathyroid hormone administration attenuates endothelial dysfunction in old rats.

Authors:  John J Guers; Rhonda D Prisby; David G Edwards; Shannon Lennon-Edwards
Journal:  J Appl Physiol (1985)       Date:  2016-11-04

2.  Mechanisms of vasodilation to PTH 1-84, PTH 1-34, and PTHrP 1-34 in rat bone resistance arteries.

Authors:  T Benson; T Menezes; J Campbell; A Bice; B Hood; R Prisby
Journal:  Osteoporos Int       Date:  2016-01-05       Impact factor: 4.507

3.  Retreatment with teriparatide: our experience in three patients with severe secondary osteoporosis.

Authors:  D L Mana; M B Zanchetta; J R Zanchetta
Journal:  Osteoporos Int       Date:  2016-12-14       Impact factor: 4.507

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.